The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review by Zenner, D
4/6/2018 Eurosurveillance | The effectiveness and cost­effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review
http://www.eurosurveillance.org/content/10.2807/1560­7917.ES.2018.23.14.17­00542 1/24
We use cookies to track usage and preferences. I Understand
Introduction
 
Tuberculosis (TB) is a public health priority in the European Union (EU) and
European Economic Area (EEA), and countries have committed themselves to the
World Health Organization (WHO) End TB Strategy with an ambitious goal to end
TB [1-4]. The foreign-born population make up an increasing and considerable
number and proportion of all TB cases in countries with low TB incidence (< 10
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Methods
cases/100,000 population) and challenge TB elimination efforts in the EU/EEA
[3,5]. More than one quarter of reported TB cases in 2015 in the EU/EEA occurred
in the foreign-born population [5]. This proportion has been increasing steadily; in
2007, 13.6% of TB cases occurred in migrant populations whereas in 2013, they
accounted for 21.8% [6]. In many low TB incidence countries in the EU/EEA, more
than half of all TB cases occur among foreign-born individuals [5]. Between 2007
and 2012, the EU/EEA received on average 1.5 million migrants from outside of
the EU/EEA, and larger numbers in 2015 and 2016 [7,8]. As a result, the foreign-
born population now makes up 11.4% of the population in the EU/EEA and
exceeds 15% in many low TB incidence countries [7,8]. A considerable proportion
of these migrants were born in countries with a high TB burden [9,10].
Given the disproportionate TB case noti〰㰊cations in migrant populations and the
faster decline of TB rates in host populations, enhanced TB control strategies
among migrants will be necessary to achieve TB elimination in the EU/EEA
(de〰㰊ned as achieving a rate of less than one case of TB per 1,000,000 population)
[1-4,11,12]. Countries have generally focused on two targeted control strategies
among migrants: (i) identi〰㰊cation of active TB with chest radiography (CXR) before
or soon after arrival in the host country to detect prevalent TB cases and limit
onward transmission and (ii) more recently, identifying and treating latent TB in
migrants from high TB burden countries to prevent TB reactivation [13]. Many
EU/EEA countries with low TB incidence screen migrants for active TB on or soon
after arrival. The migrant groups targeted for screening and the location of
screening are different for each country because screening guidelines for active
TB in migrants are lacking at the EU/EEA level [13-15]. We conducted a systematic
review on the effectiveness and a second systematic review on the cost-
effectiveness of screening for active TB among migrants in the EU/EEA region
with the aim of informing migrant screening guidelines.
 
 
Overall approach and key questions
This review supports a project of the European Centre for Disease Prevention and
Control (ECDC) to develop guidance on screening for six infectious diseases
(chronic hepatitis C, hepatitis B, HIV, TB (active and latent) and intestinal
parasites) in newly arrived migrants to the EU/EEA. The project followed the new
Grading of Recommendations Assessment, Development and Evaluation (GRADE)-
ADOLOPMENT approach to conduct systematic reviews on screening migrant
populations for these six infectious diseases [16]. The review protocol and the
methods of GRADE-ADOLOPMENT guideline development have been published
[16,17]. All reviews followed a Cochrane methodological approach and the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
methods for reporting systematic reviews [18]. For each review, we developed two
research questions (using a population, intervention, comparison and outcome
(PICO) framework), an analytic framework to illustrate the screening evidence
pathway, and identi〰㰊ed and prioritised clinically important outcomes, following the
evidence-based review methods described by the United States (US) Preventative
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CXR: chest radiography; NNS: number needed to screen; TB: tuberculosis.
Task Force [19,20]. We sought to answer two research questions: (i) what is the
effectiveness of screening migrants arriving and living in the EU/EEA for active TB
and (ii) what is the resource use, cost and cost-effectiveness of screening
migrants for active TB? We developed an analytic framework that identi〰㰊ed the
evidence chain to address the effectiveness and cost-effectiveness of active TB
screening among migrants (Figure 1) [17]. We developed the following key
questions along this evidence chain: (i) what is the yield of active TB screening
with CXR in migrants, (ii) what are the test performance characteristics of CXR to
detect active TB, (iii) how effective is active TB therapy and what are the
associated harms, (iv) what is the uptake of active TB screening by migrants, and
(v) how cost-effective is screening for active TB in migrants [17]?
Figure 1 Analytic framework of the evidence chain for active tuberculosis
screening in migrants
 
Search strategy and selection criteria
Following the GRADE-ADOLOPMENT process, we identi〰㰊ed an evidence review
that assessed the effectiveness of latent TB infection (LTBI) screening among
migrants, published in 2011 by the Canadian Collaboration on Immigrant and
Refugee Health (CCIRH), and used this as a starting point for our literature search
(anchoring review) [16,21]. The CCIRH review included systematic reviews on the
effectiveness of LTBI screening in migrants up to 2008 but did not review cost-
effectiveness. We therefore conducted two separate searches to address our
research questions. The 〰㰊rst search updated the CCIRH evidence review and
identi〰㰊ed systematic reviews and guidelines on the effectiveness and cost-
effectiveness of TB screening programmes in migrant populations from 2005 to
2016. The second search identi〰㰊ed individual studies on the resource use, costs
and cost-effectiveness of TB screening programmes for migrants over a longer
period, 2000 to 2016, given these topics were not covered in the CCIRH evidence
review. For the 〰㰊rst search, MEDLINE via Ovid, Embase, the Cumulative Index to
Nursing and Allied Health Literature (CINAHL), Epistemonikos and Cochrane
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CENTRAL between 1 January 2005 and 12 May 2016 were searched. We used a
combination of key terms including: ‘tuberculosis’, ‘screening’, ‘chest-radiograph’,
‘tuberculin skin test’, ‘interferon-gamma release assays’, ‘costs’, ‘cost-
effectiveness’ AND ‘guidelines’ and ‘reviews’. The search terms and strategy in
Ovid MEDLINE are included in Supplement 1. We also searched grey literature
websites for published guidelines and reports from the US Centres for Disease
Control and Prevention (CDC), ECDC, WHO and the International Union Against
Tuberculosis and Lung Disease (IUATLD). We did not apply language restrictions
to the search. Additional guidelines and studies were identi〰㰊ed by our co-authors
and through searching bibliographies of included studies. In the second search,
using the search terms ‘tuberculosis’, ‘screening’, ‘costs’ and ‘cost-effectiveness’,
we searched MEDLINE, Embase, the National Health Service Economic Evaluation
Database (NHS EED), the Database of Abstracts of Reviews of Effects (DARE), the
Tufts Medical Center Cost-Effectiveness Analysis Registry and Google Scholar for
entries between 1 January 2000 and 31 May 2016.
Study selection and quality assessment
We identi〰㰊ed and included systematic reviews and evidence-based guidelines that
directly addressed each key question along the active TB screening evidence
chain and prioritised documents focusing on newly arrived (< 5 years in the host
country) migrants. Migrant populations included were non-forced economic
migrants, and refugees, asylum seekers and illegal migrants who may have been
forced to ‾䐴ee con‾䐴ict, natural disaster, or economic peril [17]. We only included
studies published in full and in English or French. If more than one version of a
systematic review was identi〰㰊ed, the most recent was considered. Studies were
excluded if they were not relevant to the key questions, if they were not a
systematic review or guideline, if the study methodology was unclear, and if they
focussed only on non-generalisable subgroups (such as healthcare workers or
HIV-positive people) or addressed only latent TB screening. Two authors screened
the titles and abstracts, assessed selected full-text articles for eligibility and
extracted data from included articles. Disagreements were resolved by consensus
or by a third author. The methodological quality of systematic reviews was
assessed using the AMSTAR tool (A Measurement Tool to Assess Systematic
Reviews) and the quality of individual studies was assessed with the Newcastle-
Ottawa scale [22,23]. The GRADE criteria were applied to assess the quality and
certainty of the evidence for the individual studies included in the systematic
reviews [24].
Data extraction and synthesis
The following information was extracted from each study: study design,
objectives, analyses, quality assessment of the individual studies included in the
systematic review, population examined, number of included studies, total number
of participants included, intervention, outcome and results. We created GRADE
evidence pro〰㰊les and summary of 〰㰊ndings tables for each outcome where
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Results
appropriate. Numbers needed to screen (NNS) were estimated by calculating
1/mean prevalence of active TB found through CXR screening strati〰㰊ed by TB
incidence in the country of origin as reported in the study by Aldridge et al. [25].
For each of the cost-effectiveness studies, we extracted the following data:
economic methods used (e.g. micro-costing study, within-trial cost-utility analysis,
Markov model), description of the case base population, the intervention and
comparator, the absolute size and relative difference in resource use and cost-
effectiveness (e.g. incremental net bene〰㰊t (INB) or incremental cost-effectiveness
ratio (ICER)) [26]. The certainty of economic evidence in each study was assessed
using the relevant items from the 1997 Drummond checklist [27]. All currencies
were converted to 2015 Euros using the Cochrane web-based currency conversion
tool: https://eppi.ioe.ac.uk/costconversion/default.aspx.
 
 
In the 〰㰊rst search, we retrieved 3,375 studies through database searching and 22
additional studies identi〰㰊ed through other sources on the effectiveness of TB
screening in migrant populations (Figure 2). After removal of duplicates, 2,884
studies were screened by title and abstract. A total of 127 studies underwent full
text assessment. We did not identify any single study on the effectiveness of
active TB screening in migrants. We therefore included seven studies that
addressed the active TB screening evidence chain: the yield of detecting active TB
among migrants in CXR screening programmes (n = 3) [25,28,29], the performance
characteristics of CXR to detect active TB (n = 2) [30,31], the effectiveness of TB
therapy in those born in the EU/EEA and the foreign-born population (n = 1) [6], and
the uptake of active TB screening by migrants (n = 1) [32]. In the second search,
2,856 articles were retrieved through database searching and an additional 13
articles identi〰㰊ed through other resources (Figure 3). After removal of duplicates,
2,740 studies were screened by title and abstract. A total of 37 studies underwent
full text assessment and three individual studies were included for analysis [33-
35].
Figure 2 PRISMA ‾䐴ow diagram, literature search for the effectiveness and
cost-effectiveness of active tuberculosis screening, 1 January 2005–12 May
2016
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CINAHL: Cumulative Index to Nursing and Allied Health Literature; LTBI: latent
tuberculosis infection.
 
Figure 3 PRISMA ‾䐴ow diagram, literature search for the resource use, costs
and cost-effectiveness of active tuberculosis screening, 1 January 2000–31
May 2016
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LTBI: latent tuberculosis infection; NHS EED: National Health Service
Economic Evaluation Database; Tufts CEA: Tufts Medical Center Cost-
Effectiveness Analysis Registry.
 
Effectiveness of active tuberculosis screening
Yield of chest radiography to detect active tuberculosis
Three systematic reviews assessed the yield of detecting active TB among
migrant populations in CXR screening programmes performed before and after
arrival in the EU/EEA and low TB incidence countries outside the EU/EEA
[25,28,29]. The yield of active TB was heterogeneous across studies, varied by
migrant type and the setting in which the screening was done and was
consistently higher with higher TB incidence in the country of origin (Table 1).
Study Certainty of
evidence
Design Population Intervention/outcomes Results
Table 1
Characteristics of included studies for effectiveness of active tuberculosis
screening
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Klinkenberg
et al. 2009
[29]
Quality of
systematic
review
(AMSTAR):
3/11.
Quality of data
of included
individual
studies
(GRADE): low.
Systematic
review
1998–2008.
Observational
studies:
EU/EEA (n = 
36), non-EU
(n = 14).
EU countries
included:
Belgium,
Denmark,
France,
Germany,
Greece,
Ireland, Italy,
the
Netherlands,
Norway,
Spain,
Switzerland,
UK.
New entrants to the EU/EEA: migrant,
asylum seeker, foreign-born citizen,
illegal foreigner/migrant.
Non-EU were performed in the US,
Canada, Australia and Japan.
Type of screening: mandatory (n = 
24,156), voluntary: (n = 2,855).
Type of migrant: asylum seekers: (n = 
17,824), other migrants: (n = 5,925),
migrants/asylum seekers (n = 218,565).
Intervention: screening
by CXR (at port of arrival,
reception/holding/transit
centre, community post-
arrival, occasional
screening, follow-up
screening).
Outcomes: yield of
active TB/100,000, 95%
CI, median and IQR.
Median active TB
yield/100,000, (IQR):
EU countries: 350
(110–710), non-EU
countries: 510
(170–1,230).
Screening type:
mandatory (EU): 280
(100–420);
voluntary (EU): 400
(160–980).
Migrant type (EU):
asylum seeker: 350
(250–410), other
migrant: 170 (100–
630),
migrant/asylum
seeker: 300 (9–
500).
Screening setting
(EU): port of arrival:
360 (100–520), port
of arrival and
community post
arrival: 650 (0–0),
reception/holding
centre: 290 (100–
380), community
post arrival: 220
(100–380), follow-
up: 120 (90–170),
occasional: 1,720
(730–2,740), port of
arrival and
occasional: 720
(710–1,000).
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Arshad et
al. 2010
[28]
Quality of
systematic
review
(AMSTAR):
7/11.
Quality of data
of included
individual
studies
(GRADE):
low–very low.
Systematic
review up to
July 2008.
Observational
studies (n = 
22).
EU countries
included:
Belgium
Denmark,
Ireland, the
Netherlands,
Norway,
Spain,
Switzerland,
UK.
Migrants assessed through active case
〰㰊nding or active screening programme
irrespective of symptoms.
n = 5,446 pulmonary TB,
n = 2,620,739 screened migrants.
Total types of migrants screened:
asylum seekers (n = 135,265), regular
immigrants (n = 2,466,492), refugees (n 
= 18,982).
Intervention: CXR and/or
sputum smear and/or
microbiological culture;
routine screening
programmes/on purpose
screening.
Outcome: number of
cases detected per
100,000 individuals
screened (95% CI).
RR: pooled prevalence
for pulmonary
tuberculosis among
screened migrants
compared with general
population in host
country (95% CI).
Active TB
yield/100,000 (95%
CI): 349 (290–408);
RR (95% CI): 48.2
(23.3–99.6).
Immigrant class:
refugees: 1,192
(668–1,717); RR
130.6 (58.8–290.2),
migrants: 284 (204–
364); RR 29.4 (9.7-
88.9), asylum
seekers: 270 (198–
342); RR 30.1 (19.3–
47.1).
European
countries/immigrant
class: refugees: 577
(206–949),
migrants: 225 (129–
322), asylum
seekers: 267 (194–
341).
Region of origin:
Europe: 236 (131–
340), Africa: 655
(319–990), Asia:
1,117 (625–1,608).
Aldridge et
al. 2014
[25]
Quality of
systematic
review
(AMSTAR):
8/11.
Quality of data
of included
individual
studies
(GRADE): very
low.
Systematic
review
1980–2014.
n = 15
studies.
Migrants, asylum seekers, foreign-born
citizens, undocumented foreigners or
migrants.
3,739,266 migrants screened between
1982 and 2010: min 873– max
3,092,729 culture-con〰㰊rmed.
Types of migrants screened: migrants
(n = 592,673); refugees (n = 52,991),
mixed (n = 3,092,729), adoptees: n = 
873).
Interventions: CXR,
culture, smear for acid-
fact bacilli, drug-
resistant disease, LTBI
(any method).
Outcome: yield of
culture-con〰㰊rmed active
TB per 100,000 by TB
prevalence in country of
origin.
TB
incidence/100,000
person-years at 7
years post
migration: Africa:
190, Asia: 80, 
Somalia: 520,
Pakistan: 160,
Vietnam: 210,
Former Yugoslavia:
40/100,000.
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Van’t Hoog
et al. 2013
[30]
Quality of
systematic
review
(AMSTAR):
6/11.
Quality of data
of included
individual
studies
(GRADE): very
low.
Systematic
review
1992–2012.
n = 17 studies
(24
publications),
11
community
prevalence
surveys.
Adults (> 15 years) or general population
undergoing 〰㰊rst screening (HIV-negative
and unknown HIV status).
Median: 8,044 participants,
IQR: 98–20,566.
Intervention: symptoms,
CXR, combinations.
Outcomes: sensitivity
and speci〰㰊city (95% CI)
to detect active TB.
CXR screening had
greater accuracy
compared with
symptoms
screening.
CXR with any
abnormality:
sensitivity (95% CI):
97.8% (95.1–100.0),
speci〰㰊city (95% CI):
75.4% (72.0–78.8).
CXR with
abnormality
suggestive of TB:
sensitivity: 86.8%
(79.2–94.5),
speci〰㰊city: 89.4%
(86.7–92.0).
Any symptom
screening: 
High HIV/SSA:
sensitivity: 84.2%
(75.6–92.7),
speci〰㰊city: 74.0%
(53.1–94.9).
Low HIV/Asia:
sensitivity: 69.8%
(57.9–81.8),
speci〰㰊city: 60.6%
(34.7–86.0).
Low and high HIV
combined:
sensitivity: 77.0%
(68.0–86.0),
sensitivity: 67.7%
(50.2–85.1).
Pinto et al.
2013 [31]
Quality of
systematic
review
(AMSTAR):
8/11.
Quality of data
of included
individual
studies not
mentioned but
all studies had
veri〰㰊cation
bias
(assessed by
QUADAS):
54% not
representative,
46% did not
mention
blinding.
Systematic
review
up to 2012.
n = 12 studies
with
combined
clinical and
radiographic
features, 1
with clinical
prediction
rules.
Adult patients (≥ 15 years) with possible
PTB (excluding pneumoconiosis,
malignancies, immune-mediated
in‾䐴ammatory disease or haemodialysis).
5,767 participants.
Intervention: CXR
scoring system.
Outcomes: sensitivity
and speci〰㰊city (95% CI)
with no pooling (median,
range presented),
diagnostic OR: odds of
patient with PTB and
speci〰㰊c clinical or
radiographic
feature(s)/odds without
PTB and having the
same feature(s).
Signi〰㰊cantly
associated with
pulmonary TB:
upper lobe
in〰㰊ltrates: OR (95%
CI): 3.57 (2.38–
5.37), cavities
diagnostic: OR
range: 1.97–25.66.
Scoring systems
characteristics:
sensitivity: median
96%, IQR: 93–98%,
sensitivity: median
46%, IQR: 35–50%.
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Ködmön et
al. 2016 [6]
High quality
individual
study
(assessed by 
New Castle-
Ottawa): 8/8.
Public health
surveillance
of reported
active TB
cases from
EU and EEA
countries
2007–2013.
29 countries.
Noti〰㰊ed TB cases.
527,467 TB cases reported, 491,652 with
reported country of origin, 91,925 cases
from outside EU/EEA.
Intervention: N/A.
Outcomes: successful
treatment: cured case or
treatment completed
after 12 months, death
during treatment.
Number of reported
TB treatment
outcome: EU/EEA:
86%, non-EU/EEA:
82%.
Treatment success
(24 countries):
EU/EEA: 74.6%, non-
EU/EEA: 77.4%.
Treatment failure:
EU/EEA: 2.3%, non-
EU/EEA: 0.2%.
Lost to follow-up:
EU/EEA: 6.6%, non-
EU/EEA: 5.4%.
Death during
treatment: EU/EEA:
8.2%, non-EU/EEA:
3.2%.
Mitchell et
al. 2013
[32]
Quality of
systematic
review
(AMSTAR):
3/11.
Quality of
studies judged
to have
signi〰㰊cant
degree of
heterogeneity
and reporting
and
publication
bias. The tool
used to
measure bias
was not
mentioned.
Qualitative
and
quantitative
systematic
review and
meta-
synthesis.
n = 218
studies.
(i) Risk groups found in health services
(adolescents, drug-dependent, HIV-
positive etc.).
(ii)
Congregate/occupational/environmental
(elderly, HCWs, prisoners etc.).
(iii) Behavioural/marginalised risk
groups (homeless, migrants, sex
workers etc).
33 possible risk groups.
Intervention: N/A.
Outcome: proportion of
eligible persons who
consented to undergo
TB screening, per risk-
group (equivalent of
recruitment rate).
TB screening
acceptability:
overall: > 80%,
migrants: 85%
(range: 55–96%).
Simple TB screening
(at point-of-care)
more acceptable
than referral on
multiple visits.
Inclusion of HIV
testing may be a
deterrent in some
risk groups. TB
screening and
treatment are low
priority for groups
facing housing
insecurity, addiction,
threat of violence,
deportation.
Screening in hard-to-
reach populations is
more acceptable if
bene〰㰊ts are
immediate and
tangible.
Acceptability of TB
screening is
dependent on
quality of human
interaction as well
as perceived
negative
consequences.
AMSTAR: A MeaSurement Tool to Assess systematic Reviews [22]; CI: con〰㰊dence interval; CXR: chest radiography; EEA: European Economic
Area; EU: European Union; GRADE: The Grading of Recommendations Assessment, Development and Evaluation; HCW: healthcare workers;
HIV: human immunode〰㰊ciency virus; IQR: interquartile range; LTBI: latent tuberculosis infection; N/A: not applicable; OR: odds ratio; PTB:
pulmonary TB; QUADAS: Quality Assessment of Diagnostic Accuracy Studies; RR: risk ratio; SSA: sub-Saharan Africa; TB: tuberculosis; UK:
United Kingdom; US: United States.
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Klinkenberg et al. found that the overall yield of active TB screening programmes
in migrants upon and after arrival in 26 studies done in EU/EEA countries was 350
per 100,000 population [29]. The yield differed by migrant type (asylum seekers:
median: 350/100,000; interquartile range (IQR): 250–410, and other migrants:
median: 170; IQR: 100–630) and by setting where the screening was conducted
(port of arrival: median: 360; IQR: 100–5,200, reception/holding centres: median:
290; IQR: 100–380, community post arrival: median: 220; IQR: 100–380, and
occasional screening: median: 1,720; IQR: 730–2,740). The yield varied widely also
between host countries, from as low as 110 per 100,000 in the Netherlands to as
high as 2,340 per 100,000 in Italy, probably re‾䐴ecting differences in migrant type,
country of origin and circumstances of travel in the migrants screened [36].
Arshad et al. assessed the yield of active TB screening among migrants
originating from intermediate or high TB incidence countries upon and after entry
to low TB incidence countries and found a similar overall yield of active TB case
detection of 349 per 100,00 population [28]. The yield also varied by migrant type
(refugees: 1,192; 95% con〰㰊dence interval (CI): 668–1,717, regular migrants: 284;
95% CI: 204–364 and asylum seekers: 270; 95% CI: 198–342) and TB incidence in
the country of origin (Europe: 236; 95% CI: 131–340, Africa: 655; 95% CI: 319–990
and Asia: 1,117; 95% CI: 625–1,608) [28]. Finally, Aldridge et al. assessed the yield
of CXR screening for active TB among migrants in the pre-arrival TB screening
programmes. No overall estimates were presented but the yield increased steadily
with the TB incidence in migrant source countries. The yield was 19.6 per 100,000
in migrants originating from countries with a TB incidence lower than 50 per
100,000 and 336 per 100,000 in migrants originating from countries with a TB
incidence greater than 350 per 100,000 [25]. The quality of the data in studies
included in these three systematic reviews was very low to low (GRADE).
Accuracy of chest radiography to detect active tuberculosis
We identi〰㰊ed two systematic reviews that assessed the performance of CXR to
detect active TB [30,31]. Van’t Hoog et al. showed that CXR (presence of any
abnormality) was highly sensitive (98%) and moderately speci〰㰊c (75%) to detect
active TB [30]. Screening for active TB with symptoms alone had lower sensitivity
(78%) and speci〰㰊city (68%) [30]. Pinto et al. also found that CXR to detect active
TB was highly sensitive 95% (range: 81–100%) but less speci〰㰊c 42% (range: 22–
72%) [31]. Focussing on the presence of upper lobe in〰㰊ltrates and cavities
increased the predictive value for diagnosing active TB. The certainty of the
evidence of these two studies was judged to be very low (Table 1).
Numbers needed to screen
Using inputs of the yield of CXR reported by Aldridge in the pre-arrival programmes
we estimated the NNS to detect one case of active TB in migrants strati〰㰊ed by TB
incidence in source countries (Table 2) [25]. We found that the NNS decreased
dramatically with increasing TB incidence in source countries and ranged from
5,076 in countries with a TB incidence between 50 and 149 per 100,000 to 298 in
countries with a TB incidence greater than 350 per 100,000.
Table 2
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TB prevalence in country of
origin/100,000
Yield of culture-con〰㰊rmed active
TB/100,000
95% CI NNS 95% CI
50–149 19.7 10.3–31.6 5,076 3,175–9,709
150–249 166.2 140–194 602 514–714
250–349 133.5 111–158 749 631–903
> 350 335.9 283–393 298 254–353
CI: con〰㰊dence interval; CXR: chest radiography; NNS: numbers needed to screen; TB: tuberculosis.
 The yield of active TB detection in pre-arrival CXR screening programmes for migrants by TB incidence in country of origin
from Aldrige et al. [25].
 NNS = 1/mean prevalence of active TB found through CXR screening strati〰㰊ed by TB incidence in the country of origin.
Effectiveness of active tuberculosis treatment
In an ECDC report on TB surveillance from 2007 to 2013, TB treatment outcomes
were similar or better in those born outside the EU/EEA than in those born in the
EU/EEA [6]. Treatment success was as high in the foreign-born (for all regions of
origin) compared with those born in the EU/EEA (77.4% vs 74.6%); however, their
failure rates (0.2% vs 2.4%) and default rates (5.4% to 6.6%) were lower. This
European surveillance data was judged to be high-quality evidence (Table 1).
Acceptability of screening
Mitchell et al. conducted a review to determine the acceptability of targeted TB
screening and active case 〰㰊nding among vulnerable and at-risk groups and found
that TB screening was well accepted by the majority of risk groups, including
migrants (85%; range: 55–96%). Lower acceptability was found among persons
living with HIV/AIDS and individuals in refugee camps and internally displaced
persons [32]. Overall, the study found that simple TB screening (at point of care)
was more acceptable than referral requiring multiple visits. The evidence in this
study was judged to have considerable bias (Table 1).
Cost-effectiveness of active tuberculosis screening
programmes
There was very little information on the cost-effectiveness of active TB screening
in migrant populations as only three studies were identi〰㰊ed. These studies
demonstrated that the most cost-effective CXR screening strategies were among
high-prevalence groups, close contacts of those with known TB, and migrants at
entry if they originated from intermediate (60/100,000) and high (> 120/100,000)
TB incidence countries [33-35] (Table 3).
Numbers needed to screen to detect one case of active tuberculosis
a
b
a
b
Table 3
Characteristics of included studies for resource use, costs, and cost-
effectiveness of active tuberculosis screening
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Study Certainty of economic
evidence based on
the Drummond
criteria  [27]
Methodological
approach/population
Intervention(s) Cost-
effectiveness
(ICER or INB) per
case prevented
Resource
Requirements
Schwartzman
et al. 2000 [33]
Certainty of evidence:
moderate.
Allowance was made
for uncertainty in the
estimates of costs
and consequences,
and ranges were
provided.
No PSA were
performed.
Justi〰㰊cation was
provided for a range
of values estimated in
one-way sensitivity
analyses.
The cost-
effectiveness results
were sensitive to
model inputs
including the
probability of INH
prescribed; probability
of INH treatment
completed; cost of
inpatient treatment;
TB infection rate and
HIV seropositivity.
Methods: decision-
analytic Markov
model; 20 year time
horizon; 3% discount
rate, perspective of
the third-party payer
(central and
provincial
governments);
scenario analysis
based on INH
completion
conducted.
Population: 20-year-
old immigrants to
Canada originating
from Sub-Saharan
Africa, South-east
Asia, Western
Europe.
Cohort 1: 50% TB-
positive, 10% HIV-
positive.
Cohort 2: 50% TB-
positive, 1% HIV-
positive.
Cohort 3: 5% TB-
positive, 1% HIV-
positive.
Three
strategies:
(i) No
screening
(ii) CXR
(iii) TST
Cohort 1: 
TST vs CXR: CAD
2,601(EUR
29,990);
CXR vs no
screening: CAD
3,934 (EUR
3,618).
Cohort 2:
TST vs CXR: CAD
66,759 (EUR
61,413);
CXR vs no
screening: CAD
10,627 (EUR
9,776).
Cohort 3:
TST vs CXR: CAD
68,799 (EUR
63,289);
CXR vs no
screening: CAD
236,496 (EUR
217,557).
Resource
requirements are
high in cohorts 1
and 2, and
moderate in cohort
3.
Costs/1,000
patients:
Cohort 1 (high risk):
TST: CAD 436,390
(EUR 401,444);
CXR: CAD 338,310
(EUR 311,218);
No screening: CAD
332,020 (EUR
305,432).
Cohort 2
(intermediate risk):
TST: CAD 342,730
(EUR 315,284);
CXR: CAD 231,430
(EUR 212,897);
No screening: CAD
218,250 (EUR
200,773).
Cohort 3 (low risk):
TST: CAD 62,640
(EUR 57,623);
CXR: CAD 51,170
(EUR 47,072);
No screening: CAD
21,820 (EUR
20,072).
a
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Dasgupta et
al. 2000 [34]
Certainty of evidence:
low.
Limited allowance
was made for
uncertainty in the
estimates of costs
and consequences;
ranges were provided.
No PSA was
performed
No one-way or two-
way sensitivity
analyses using higher
or lower costs, other
discount rates or
comparisons were
performed. 
Scenario analyses
undertaken.
The cost-
effectiveness results
were sensitive to
costs for passive
diagnosis of TB, INH
prescription rate,
screening referral
criteria and future risk
of active TB.
Methods: cost-
effectiveness
analysis based on
prospective non-
randomised cohorts;
results reported in
Canadian dollars;
prospective cohort
study over 1 year of
costs.
Population:
immigration
applicants
undergoing CXR
screening, already
arrived immigrants
requiring screening
for latent TB, close
contacts of active
cases resident in
Montreal, Quebec,
Canada.
Three
strategies:
(i) CXR in
migrants
applying for a
permanent
residence
(ii)
Surveillance
CXR +/− TST
(iii) Close
contacts CXR
+/− TST
Over 1 year, the
three
programmes
detected 27
cases of active
TB and prevented
14 future cases.
Close-contact
screening
resulted in net
savings
of CAD 815 (EUR
758) for each
active case
detected and
treated and of
CAD 2,186 (EUR
2,033) for each
future active case
prevented,
compared with
passive case
detection.
Resource
requirements were
moderate in
applicants and
close contacts and
higher on those on
surveillance.
Costs of TB
detected and
treated:
Close contacts CXR
+/− TST: CAD
10,275 (EUR 9,560);
Applicants CXR:
CAD 31,418 (EUR
29,232);
Those on
surveillance CXR +/
− TST: 55,728 (EUR
51,850).
Oxlade et al.
2007 [35]
Certainty of evidence:
moderate.
Allowance was made
for uncertainty in the
estimates of costs
and consequences;
ranges were provided.
No PSA was
performed
One-way or two-way
sensitivity analyses
using higher or lower
costs, other discount
rates and test
performance
characteristics were
undertaken.
The cost-
effectiveness results
were sensitive to TST
and QFT sensitivity,
costs of TST and QFT,
close contacts
investigation, the
passive TB case
detection rate and risk
of re-activation.
Methods: decision-
analytic Markov
model; 20 year time
horizon; 3% discount
rate; Canadian health
system perspective;
Costs reported in
2004 Canadian
dollars.
Population: foreign-
born entrants to
Canada; close
contacts of active
TB cases.
Five strategies:
(i) CXR
(ii) No
screening
(iii) TST
(iv) QFT
(v) TST
followed by
QFT if TST-
positive
ICER (CAD/case
prevented):
CXR vs no
screening: CAD
875 (EUR 690);
TST vs CXR: CAD
9,800 (EUR
7,738), assuming
that prescription
and completion
rates in indicated
patients were
100% (relative to
the baseline
assumption of
73% prescription
and 50%
completion).
Resource
requirement were:
low to moderate for
CXR and moderate
for QFT in
immigrants from
medium and high
incidence countries;
high for CXR and
QFT in immigrants
from low-incidence
countries.
Costs of CXR
screening ranged
from:
low TB incidence
source (2/100,000),
CAD 52,553 (EUR
41,499);
high TB incidence
(120/100,000),
CAD 328,190 (EUR
259,160).
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Discussion
CAD : Canadian dollar; CXR: chest radiography; EUR: Euro; HIV: human immunode〰㰊ciency virus; ICER: incremental cost-
effectiveness ratio; INB: incremental net bene〰㰊t; INH: isoniazid; PSA: probabilistic sensitivity analysis; QFT: quantiferon; TB:
tuberculosis; TST: tuberculin skin test; USD: United States dollar.
 The Drummond Criteria [27]: (i) Was a well-de〰㰊ned question posed in answerable form? (ii) Was a comprehensive
description of the competing alternatives given (i.e. can you tell who did what to whom, where and how often)? (iii) Was the
effectiveness of the programme or services established? (iv) Were all the important and relevant costs and consequences for
each alternative identi〰㰊ed? (v) Were costs and consequences measured accurately in appropriate physical units (e.g. hours
of nursing time, number of physician visits, lost working days, gained life years)? (vi) Were the cost and consequences valued
credibly? (vii) Were costs and consequences adjusted for differential timing? (viii) Was an incremental analysis of costs and
consequences of alternatives performed? (ix) Was allowance made for uncertainty in the estimates of costs and
consequences? (x) Did the presentation and discussion of study results include all issues of concern to users?
All currencies were converted to 2015 Euros using the Cochrane web-based currency conversion tool:
https://eppi.ioe.ac.uk/costconversion/default.aspx. Resource use was expressed in cost per person and classi〰㰊ed as low 
(savings or ≤ USD 1,000/person (EUR 808)), moderate (USD 1,000–100,000/person (EUR 808–80,845)) or high (USD ≥ 
100,000/person (EUR > 80,845)).
Two studies demonstrated that CXR screening of migrants was cost-effective
compared with no screening: Oxlade et al. determined that the ICER of CXR
relative to no screening was CAD 30,000 (Canadian dollars in 2004; EUR 23,690)
per case averted in migrants from intermediate TB incidence source countries,
and less than CAD 1,000 (EUR 789) per case averted in the high-incidence group
[35]. Similarly, CXR compared with no screening in immigrants with a risk of
reactivation of more than 5% was cost-effective. Dasgupta et al. reported that
close-contact screening resulted in net savings of CAD 815 (EUR 758) for each
active case detected and treated and of CAD 2,186 (EUR 2,033) for each future
active case prevented, compared with passive case detection [34]. The certainty of
the evidence in these studies ranged from low to moderate (Table 1).
 
 
There were no single studies that directly addressed the overall effectiveness of
active TB screening programmes on the health outcomes of migrant populations.
We therefore evaluated the screening chain of evidence. The yield of detecting
active TB through CXR screening of migrants was heterogeneous across studies
and varied by migrant type and the setting in which the screening was done, but
consistently increased with higher TB incidence in the country of origin [25,28,29].
The NNS to detect one case of active TB decreased and cost-effectiveness
increased with increasing TB incidence in source countries [25,34,35]. CXR is a
highly sensitive and moderately speci〰㰊c screening tool to detect active TB [30,31].
CXR screening is highly acceptable to most foreign-born populations [32].
The yield of CXR to detect active TB varied widely among migrant sub-groups in
the three systematic reviews (120 to 2,340/100,000) however the overall yield (350
cases/100,000) in the post-arrival setting was consistent between studies [28,29].
There was also consistency in the increase in yield with increasing TB incidence in
source countries in both pre- and post-arrival setting [25,28,29]. The majority of
studies in the post-arrival setting were carried out in various EU/EEA countries
whereas pre-arrival screening was done in migrants arriving in the United
Kingdom. The wide range in yield of post-arrival screening programmes re‾䐴ects
the heterogeneity of the programmes and the composition of migrants screened.
Post-arrival programmes differed widely between countries with respect to timing
a
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of screening (port of arrival, in reception areas, in the community or ad hoc),
countries of origin of migrants received, the type of migrants targeted (all
migrants, asylum seekers only or undocumented migrants), and the threshold of
TB incidence in the countries of origin at which screening was performed.
Although 31 EU/EEA countries have an active TB screening programme for
migrants, the absolute and attributable impact on active TB rates in those
countries is unknown [37,38]. Extrapolating from the impact of the well-
established pre-migration TB programme in the US, there may be bene〰㰊t of active
TB screening in migrants on TB control in the host country. An evaluation of this
programme demonstrated that detecting prevalent active TB before arrival in the
US reduced TB noti〰㰊cation rates among migrants in the 〰㰊rst years after arrival
[39].
Higher NNS and lower cost-effectiveness with higher TB incidence in countries of
origin suggests that active TB screening programmes will be most eㄊ橔cient when
targeting migrant populations from high TB incidence countries. This is consistent
with WHO recommendations to focus active screening on the highest risk groups
[40]. The heterogeneity of the estimates from these studies, however, limits the
ability to provide more precise guidance on which type of migrants to target, the
best timing to screen or the optimal threshold of TB incidence in countries of
origin. Although screening migrants from the highest TB incidence countries is
most eㄊ橔cient, the impact on TB incidence in the host country might be limited
since many cases occur in migrants from countries with lower TB incidence and in
migrants who entered the country many years before TB diagnosis [41,42].
Although the CXR is a good screening test for active TB and is highly sensitive
(78%), con〰㰊rmatory sputum culture for TB is essential to improve speci〰㰊city and is
the gold standard for diagnosing active TB [30,31,43]. Screening for symptoms of
active TB may be a reasonable 〰㰊rst screening tool in certain situations such as in
an emergency setting with no on-site CXR facilities. These situations include the
reception centres in Italy and Greece and/or when the receipt of a large number of
migrants overwhelm health systems (as occurred in Europe in 2015) [8]. Those
with symptoms would need referral for CXR. The choice of the screening
algorithm will need to be determined by the availability, feasibility and cost of the
tests.
Active TB case 〰㰊nding in at-risk populations is an important TB control strategy as
it allows for early detection and treatment, reduces individual morbidity and
prevents TB spread to others. Active screening programmes are, however, limited
by the fact that the yield is low (0.31–1.21%) and that they do not capture or
prevent the majority of incident TB cases occurring in the EU/EEA that are
primarily due to reactivation of latent TB or new acquisition during travel [13].
Furthermore, the epidemiology of TB in the EU/EEA is heterogeneous. While
migrants make up the majority of TB cases in low TB incidence EU/EEA countries,
they make up a minority of cases in member states with higher TB incidence
(Supplement 2). Screening for active TB in migrants will therefore need to be
tailored to the local TB epidemiology in host countries, and the healthcare capacity
in each setting [2,3]. Finally, many migrant sub-groups are vulnerable and face
barriers in accessing heath care and treatment in the EU/EEA [44]. Addressing
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Conclusions
Acknowledgements
barriers in accessing care and treatment for all migrants, including the right to
healthcare access for all and programmes tailored to address unique needs, will
be essential to ensuring the most effective active TB screening and treatment
programmes.
Study limitations
Our study was limited by the fact that we did not retrieve any studies that directly
estimated the effectiveness of active TB screening and by the very limited data on
the cost-effectiveness of active TB screening. The search was limited by the fact
that it was conducted up until May 2016 and that we only included studies
published in English or French. A recent narrative review of the effectiveness and
cost-effectiveness, however, reports similar literature and 〰㰊ndings as our study
[45]. Our 〰㰊ndings are further limited by the quality of the original studies that were
included in the systematic reviews. Study quality was low or very low, as almost all
included studies were observational studies.
Evidence gaps and future directions
Robust studies on the yield of active TB screening among migrants by age group,
migration type, timing of screening, threshold of TB incidence in source countries
and the associated cost-effectiveness will be required to design the most effective
active TB screening programmes. Additional studies are needed that determine
the absolute and attributable impact of active TB programmes on TB control in
low-incidence countries in the EU/EEA and the optimal threshold of incidence in
source countries at which to screen. Finally, evidence on the comparative
effectiveness and cost-effectiveness of different TB control strategies (active vs
latent TB screening) for migrants will be required to prioritise TB control efforts for
this population.
 
 
Active TB screening programmes that target migrants from high TB incidence
countries will provide the highest yield and will be the most cost-effective. The
heterogeneity of the estimates from the studies identi〰㰊ed and the small number of
studies addressing both the effectiveness and cost-effective of active TB
screening in migrants limits the ability to provide precise guidance on which type
of migrants to target, the best timing to screen or the optimal threshold of TB
incidence in countries of origin. This highlights the need for further data to inform
active TB screening programmes for migrants in the EU/EEA.
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